Cutler Group’s Lipocine LPCN Stock Holding History

Cutler Group’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-547	Closed	-$76K	–	7073
2016 Q2	$76K	Sell	547 -271	-33%	-$42K	﹤0.01%	1950
2016 Q1	$78K	Sell	818 -182	-18%	-$31.1K	0.01%	1863
2015 Q4	$11K	Buy	+1,000	New	+$210K	﹤0.01%	4039

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's LPCN Position: Q4 2023 in Review

Cutler Group sold out of Lipocine (LPCN) in Q4 2023, closing a stake of 765 shares — an estimated $2K sold.

Cutler Group first reported a position in LPCN in Q4 2015 and held it in 32 quarters. The position peaked at $182K in Q1 2016. 19 funds tracked by Wall St. Rank hold LPCN as of Q4 2023.

Cutler Group reported no remaining Lipocine position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 765 Lipocine shares in Q4 2023, an estimated $2K.
Cutler Group first reported a position in Lipocine in Q4 2015 and held it in 32 quarters.
Cutler Group's Lipocine position peaked at $182K in Q1 2016.
19 funds tracked by Wall St. Rank held Lipocine as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.